Dreieich

EQS-News: Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024

Retrieved on: 
Freitag, Mai 10, 2024
Birth, FDA, Phase, Pneumonia, Grifols, Technology transfer, Dreieich, Management, Fibrinogen, Immunodeficiency, Collection, Research, Community-acquired pneumonia, Factor, Biologics license application, ROCE, SCAP, Tax, Patient, Next Level, Health, Plasma, Disclosure, Video game

The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 2024 financial year.

Key Points: 
  • The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 2024 financial year.
  • EBIT for the first quarter of 2024 amounted to € 52.8 million, a significant improvement on the first quarter of the previous year (prior year period: € - 9.1 million).
  • The financial result for the first quarter of the current year deteriorated by € -1.4 million to € -10.7 million (prior-year period: € -9.3 million).
  • The Biotest Group's earnings after taxes improved to € 29.5 million in the first quarter of 2024 after € -20.4 million in the same quarter of the previous year due to the influencing factors described above.

EQS-News: Biotest AG increased sales by 32% in the financial year 2023

Retrieved on: 
Mittwoch, April 10, 2024
Primary immunodeficiency, PLI, Tax, EBT, Growth, Biologics license application, Dreieich, Partnership, Patient, Research, Grifols, Management, Technology transfer, Disclosure, PID, Annual report, Next Level, S.A, Birth, FDA, BLA, Fibrinogen, Factor

In the financial year 2023, the Biotest Group generated revenue of € 684.6 million compared with € 516.1 million in the previous year.

Key Points: 
  • In the financial year 2023, the Biotest Group generated revenue of € 684.6 million compared with € 516.1 million in the previous year.
  • The consolidated EBIT result in the 2023 financial year of € 143.5 million improved considerably compared with € -16.6 million in the previous year.
  • In September 2023, Biotest reached an important milestone in the marketing authorisation process for Yimmugo® in the USA.
  • The 2023 Annual Report and the 2023 Sustainability Report are available on the company's website.

EQS-News: Biotest AG: Biotest receives approval for innovative immunoglobulin Yimmugo® in the UK

Retrieved on: 
Montag, September 25, 2023
Dreieich, United Kingdom, Quality of life, Immunomodulation, AG, Senior, Patient, Safety, Marketing, Pharmaceutical industry

"We are delighted that this approval gives us the opportunity to launch our new immunoglobulin in another important European market," said Enrico D'Aiuto, Senior Vice President, Head of Global Sales and Marketing.

Key Points: 
  • "We are delighted that this approval gives us the opportunity to launch our new immunoglobulin in another important European market," said Enrico D'Aiuto, Senior Vice President, Head of Global Sales and Marketing.
  • "This will help us to meet the growing demand for immunoglobulin therapies, provide even more patients with our new immunoglobulin and thus contribute to improving their quality of life."
  • The new immunoglobulin is the first product to be manufactured using an innovative process in the new "Biotest Next Level" production facility at the Dreieich site.
  • It has been investigated in extensive approval studies for safety, efficacy and tolerability.

EQS-News: Biotest AG: Biotest increases EBIT to Euro 19.8 million

Retrieved on: 
Donnerstag, Juli 27, 2023
Tax, EBIT, Sale, Next Level, Plasma, EBITDA, Dreieich, Depreciation, Technology transfer, Grifols

In the first half of the 2023 financial year, the Biotest Group recorded sales revenues of € 275.3 million.

Key Points: 
  • In the first half of the 2023 financial year, the Biotest Group recorded sales revenues of € 275.3 million.
  • This corresponds to an increase of 8.8 % compared to the sales of € 253.1 million in the same period of the previous year.
  • The main reason for this development was the gain of € 23.1 million from the sale of five Biotest subsidiaries to Grifols.
  • Biotest will publish the full figures for the first half of the 2023 financial year on 10 August 2023.

EQS-News: Biotest AG: Biotest core business profitable at Euro 60.7 million

Retrieved on: 
Donnerstag, März 23, 2023
ROCE, Saskatchewan River Sturgeon Management Board, Czech Republic, Antibody, Annual, Fibrinogen, Next Level, Plasma, RTÉ Executive Board, Patient, Annual report, Dreieich, III, Safety, Pharmaceutical industry, Fine chemical, Cryptocurrency, EBIT

First product from Biotest Next Level facility: approval and market launch of Yimmugo in November 2022

Key Points: 
  • First product from Biotest Next Level facility: approval and market launch of Yimmugo in November 2022
    Dreieich, 23 March 2023.
  • In the financial year 2022, the Biotest Group slightly increased its sales revenue to € 516.1 million after € 515.6 million in the previous year.
  • The profitability of the Biotest Group's core business (adjusted EBIT) is steadily growing and clearly profitable at € 60.7 million (previous year: € 29.4 million) which is in the upper range of the forecast range of € 40 to 70 million.
  • In the Biotest Next Level expansion project, Biotest has set the course for a positive corporate development.

EQS-News: Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation)

Retrieved on: 
Sonntag, November 27, 2022
Degenerative disease, Paul Ehrlich Institute, PID, Immunomodulation, SID, VIII, MMN, Dreieich, Multifocal motor neuropathy, Natural Resources, Physician, Patient, Progressive lens, Immunoglobulin G, GBS, Chronic inflammatory demyelinating polyneuropathy, Fibrinogen, Guillain, IVIG, CIDP, ITP, Plasma, Safety, Pharmaceutical industry, Vaccine, Primary

BiotestAG announced today that the German competent authority, the Paul-Ehrlich-Institute, has approved the new intravenous immunoglobulin Yimmugo (IgGNextGeneration) in Germany.

Key Points: 
  • BiotestAG announced today that the German competent authority, the Paul-Ehrlich-Institute, has approved the new intravenous immunoglobulin Yimmugo (IgGNextGeneration) in Germany.
  • "Biotest is expanding its immunoglobulin product portfolio with an innovative new product.
  • Yimmugo offers patients and physicians another important treatment option whose safety, efficacy and tolerability have been proven in the approval studies," emphasises Dr Jrg Schttrumpf, Chief Scientific Officer of Biotest AG.
  • Yimmugo is a newly developed polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIG).

DGAP-News: Biotest AG: Biotest combats climate change through CO2-neutral production

Retrieved on: 
Mittwoch, Januar 19, 2022
COO, Electricity, Running, Plant, Climate change, Ashden, Goal, Dreieich, Environment, Renewable energy, Coal

Biotest AG is actively involved in the fight against climate change at the Dreieich site through targeted measures.

Key Points: 
  • Biotest AG is actively involved in the fight against climate change at the Dreieich site through targeted measures.
  • When implementing the optimisation potential in a fully continuous production operation, weighing up the potential, technical possibility and time feasibility is a major challenge.
  • In order to make the remaining energy consumption climate-neutral despite all the measures listed, Biotest always obtains its electricity (approx.
  • The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

DGAP-News: Biotest AG: Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.

Retrieved on: 
Freitag, November 5, 2021
West Coast of Vancouver Island Aquatic Management Board, Fairness opinion, Rothschild, Bidding, Research, Supervisory board, Review, Rothschild & Co, Dreieich, Property management, Audit

Biotest AG: Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.

Key Points: 
  • Biotest AG: Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.
  • Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.
    Dreieich, 5 November 2021.
  • Today, the Management Board and the Supervisory Board of Biotest AG ("Biotest") have published their joint reasoned statement pursuant to Section 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und bernahmegesetz) on the offer document of GRIFOLS, S.A. ("Bidder") dated 26 October 2021.
  • In this statement, the Management Board and the Supervisory Board recommend, after a careful review process, to the shareholders to accept the offer.

DGAP-News: Biotest AG: Biotest receives manufacturing license for new production facility and plans to hire 150 additional employees

Retrieved on: 
Dienstag, Juli 13, 2021
Glycoproteins, Dreieich, Offenbach, Antibody

The manufacturing of the products can thus begin in the new production facilities.

Key Points: 
  • The manufacturing of the products can thus begin in the new production facilities.
  • The final steps for the market approval of our new IgG Next Generation immunoglobulin still need to be completed.
  • Biotest is looking for 150 additional employees for the start-up and operation of the new facility at the Dreieich site.
  • With the investment programme "Biotest Next Level", Biotest will more than double the total production capacity of the Biotest Group.

DGAP-News: Biotest AG: Biotest Supervisory Board extends contracts with the Board of Management

Retrieved on: 
Montag, Juli 20, 2020
Dreieich, Offenbach, Corporations, Business, Supervisory board, Board of directors, Articles

Biotest AG announces today that the Supervisory Board of Biotest AG, Dreieich, has extended the appointment of its two Management Board members.

Key Points: 
  • Biotest AG announces today that the Supervisory Board of Biotest AG, Dreieich, has extended the appointment of its two Management Board members.
  • The new term of office and Management Board contract of Dr. Michael Ramroth (59) has a term of three years until December 31, 2023.
  • The term of office and the Management Board contract of Dr. Georg Flo (59) was extended by two years until January 8, 2023.
  • "The cooperation between the Supervisory Board and the Management Board is based on trust, is open and always result-oriented.